Global (United States, European Union and China) Dravet Syndrome Treatment Market Research Report 2019-2025
Table of Contents
1 Report Overview
- 1.1 Study Scope
- 1.2 Major Manufacturers Covered in This Report
- 1.3 Market Segment by Type
- 1.3.1 Global Dravet Syndrome Treatment Market Size Growth Rate by Type (2019-2025)
- 1.3.2 First-generation Drug (FGD)
- 1.3.3 Second-generation Drug (SGD)
- 1.3.4 Third-generation Drug (TGD)
- 1.4 Market Segment by Application
- 1.4.1 Global Dravet Syndrome Treatment Market Share by Application (2019-2025)
- 1.4.2 Hospital Pharmacy
- 1.4.3 Retail Pharmacy
- 1.4.4 E- Commerce
- 1.4.5 Others
- 1.5 Study Objectives
- 1.6 Years Considered
2 Global Growth Trends
- 2.1 Global Dravet Syndrome Treatment Market Size
- 2.1.1 Global Dravet Syndrome Treatment Revenue 2014-2025
- 2.1.2 Global Dravet Syndrome Treatment Sales 2014-2025
- 2.2 Dravet Syndrome Treatment Growth Rate by Regions
- 2.2.1 Global Dravet Syndrome Treatment Sales by Regions 2014-2019
- 2.2.2 Global Dravet Syndrome Treatment Revenue by Regions 2014-2019
- 2.3 Industry Trends
- 2.3.1 Market Top Trends
- 2.3.2 Market Drivers
3 Market Share by Manufacturers
- 3.1 Dravet Syndrome Treatment Sales by Manufacturers
- 3.1.1 Dravet Syndrome Treatment Sales by Manufacturers 2014-2019
- 3.1.2 Dravet Syndrome Treatment Sales Market Share by Manufacturers 2014-2019
- 3.2 Revenue by Manufacturers
- 3.2.1 Dravet Syndrome Treatment Revenue by Manufacturers (2014-2019)
- 3.2.2 Dravet Syndrome Treatment Revenue Share by Manufacturers (2014-2019)
- 3.2.3 Global Dravet Syndrome Treatment Market Concentration Ratio (CR5 and HHI)
- 3.3 Dravet Syndrome Treatment Price by Manufacturers
- 3.4 Key Manufacturers Dravet Syndrome Treatment Plants/Factories Distribution and Area Served
- 3.5 Date of Key Manufacturers Enter into Dravet Syndrome Treatment Market
- 3.6 Key Manufacturers Dravet Syndrome Treatment Product Offered
- 3.7 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
- 4.1 Sales and Revenue for Each Type
- 4.1.1 First-generation Drug (FGD) Sales and Revenue (2014-2019)
- 4.1.2 Second-generation Drug (SGD) Sales and Revenue (2014-2019)
- 4.1.3 Third-generation Drug (TGD) Sales and Revenue (2014-2019)
- 4.2 Global Dravet Syndrome Treatment Sales Market Share by Type
- 4.3 Global Dravet Syndrome Treatment Revenue Market Share by Type
- 4.4 Dravet Syndrome Treatment Price by Type
5 Market Size by Application
- 5.1 Overview
- 5.2 Global Dravet Syndrome Treatment Sales by Application
6 United States
- 6.1 United States Dravet Syndrome Treatment Breakdown Data by Company
- 6.2 United States Dravet Syndrome Treatment Breakdown Data by Type
- 6.3 United States Dravet Syndrome Treatment Breakdown Data by Application
7 European Union
- 7.1 European Union Dravet Syndrome Treatment Breakdown Data by Company
- 7.2 European Union Dravet Syndrome Treatment Breakdown Data by Type
- 7.3 European Union Dravet Syndrome Treatment Breakdown Data by Application
8 China
- 8.1 China Dravet Syndrome Treatment Breakdown Data by Company
- 8.2 China Dravet Syndrome Treatment Breakdown Data by Type
- 8.3 China Dravet Syndrome Treatment Breakdown Data by Application
9 Rest of World
- 9.1 Rest of World Dravet Syndrome Treatment Breakdown Data by Company
- 9.2 Rest of World Dravet Syndrome Treatment Breakdown Data by Type
- 9.3 Rest of World Dravet Syndrome Treatment Breakdown Data by Application
- 9.4 Rest of World Dravet Syndrome Treatment Breakdown Data by Countries
- 9.4.1 Rest of World Dravet Syndrome Treatment Sales by Countries
- 9.4.2 Rest of World Dravet Syndrome Treatment Revenue by Countries
- 9.4.3 Japan
- 9.4.4 Korea
- 9.4.5 India
- 9.4.6 Southeast Asia
10 Company Profiles
- 10.1 Biocodex
- 10.1.1 Biocodex Company Details
- 10.1.2 Company Description and Business Overview
- 10.1.3 Sales, Revenue and Market Share of Dravet Syndrome Treatment
- 10.1.4 Dravet Syndrome Treatment Product Introduction
- 10.1.5 Biocodex Recent Development
- 10.2 Epygenix Therapeutics
- 10.2.1 Epygenix Therapeutics Company Details
- 10.2.2 Company Description and Business Overview
- 10.2.3 Sales, Revenue and Market Share of Dravet Syndrome Treatment
- 10.2.4 Dravet Syndrome Treatment Product Introduction
- 10.2.5 Epygenix Therapeutics Recent Development
- 10.3 GW Pharmaceuticals
- 10.3.1 GW Pharmaceuticals Company Details
- 10.3.2 Company Description and Business Overview
- 10.3.3 Sales, Revenue and Market Share of Dravet Syndrome Treatment
- 10.3.4 Dravet Syndrome Treatment Product Introduction
- 10.3.5 GW Pharmaceuticals Recent Development
- 10.4 OPKO Health
- 10.4.1 OPKO Health Company Details
- 10.4.2 Company Description and Business Overview
- 10.4.3 Sales, Revenue and Market Share of Dravet Syndrome Treatment
- 10.4.4 Dravet Syndrome Treatment Product Introduction
- 10.4.5 OPKO Health Recent Development
- 10.5 Zogenix
- 10.5.1 Zogenix Company Details
- 10.5.2 Company Description and Business Overview
- 10.5.3 Sales, Revenue and Market Share of Dravet Syndrome Treatment
- 10.5.4 Dravet Syndrome Treatment Product Introduction
- 10.5.5 Zogenix Recent Development
11 Value Chain and Sales Channels Analysis
- 11.1 Value Chain Analysis
- 11.2 Sales Channels Analysis
- 11.2.1 Dravet Syndrome Treatment Sales Channels
- 11.2.2 Dravet Syndrome Treatment Distributors
- 11.3 Dravet Syndrome Treatment Customers
12 Market Forecast
- 12.1 Global Dravet Syndrome Treatment Sales and Revenue Forecast 2019-2025
- 12.2 Global Dravet Syndrome Treatment Sales Forecast by Type
- 12.3 Global Dravet Syndrome Treatment Sales Forecast by Application
- 12.4 Dravet Syndrome Treatment Forecast by Regions
- 12.4.1 Global Dravet Syndrome Treatment Sales Forecast by Regions 2019-2025
- 12.4.2 Global Dravet Syndrome Treatment Revenue Forecast by Regions 2019-2025
- 12.5 United States Market Forecast
- 12.6 European Union Market Forecast
- 12.7 China Market Forecast
- 12.8 Rest of World
- 12.8.1 Japan
- 12.8.2 Korea
- 12.8.3 India
13 Research Findings and Conclusion
14 Appendix
- 14.1 Research Methodology
- 14.1.1 Methodology/Research Approach
- 14.1.1.1 Research Programs/Design
- 14.1.1.2 Market Size Estimation
- 14.1.1.3 Market Breakdown and Data Triangulation
- 14.1.2 Data Source
- 14.1.2.1 Secondary Sources
- 14.1.2.2 Primary Sources
- 14.1.1 Methodology/Research Approach
- 14.2 Author Details
Dravet syndrome is a rare, severe form of intractable epilepsy. It occurs due to a mutation in the SCN1A gene, which is required for the proper function of brain cells.
Although there is no cure for Dravet syndrome, most treatments aim to reduce seizures. First line anti-seizure medications include clobazam (Onfi, Frisium) and valproic acid (Depakote, Depakene). Second line treatments include stiripentol (Diacomit), topiramate (Topamax), and the ketogenic diet.
In 2019, the market size of Dravet Syndrome Treatment is xx million US$ and it will reach xx million US$ in 2025, growing at a CAGR of xx% from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.
In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Dravet Syndrome Treatment.
This report studies the global market size of Dravet Syndrome Treatment, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
This study presents the Dravet Syndrome Treatment sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.
For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.
In global market, the following companies are covered:
Biocodex
Epygenix Therapeutics
GW Pharmaceuticals
OPKO Health
Zogenix
...
Market Segment by Product Type
First-generation Drug (FGD)
Second-generation Drug (SGD)
Third-generation Drug (TGD)
Market Segment by Application
Hospital Pharmacy
Retail Pharmacy
E- Commerce
Others
Key Regions split in this report: breakdown data for each region.
United States
China
European Union
Rest of World (Japan, Korea, India and Southeast Asia)
The study objectives are:
To analyze and research the Dravet Syndrome Treatment status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.
To present the key Dravet Syndrome Treatment manufacturers, presenting the sales, revenue, market share, and recent development for key players.
To split the breakdown data by regions, type, companies and applications
To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
To identify significant trends, drivers, influence factors in global and regions
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market
In this study, the years considered to estimate the market size of Dravet Syndrome Treatment are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025